Global Cancer Monoclonal Antibodies Market - 2021-2028

Global Cancer Monoclonal Antibodies Market - 2021-2028

Market Overview

The Global Cancer Monoclonal Antibodies market is expected to grow at a CAGR of 11.86% during the forecast period (2021-2028).

Cancer monoclonal antibodies are highly specific to cancer cells, as they bind to the proteins on their surface and stimulate an immune response. Therefore, monoclonal antibodies are highly customizable due to its specific nature and can play a crucial role in eliminating the cancerous cell while sparing the normal cells during the cancer treatment. Hence, monoclonal antibodies technology is proved to be more effective than other cancer therapies.

Market Dynamics

The global ECG market growth is driven by the the growing prevalence of cancer, increasing investment in R&D of genomic studies, and rising advancements in and preference toward the specificity of monoclonal antibodies to target cancer.

The growing prevalence of cancer and extensive R&D in the field of cancer monoclonal antibodies will drive the market growth

Increase in prevalence of cancer worldwide is the primary factor driving the cancer monoclonal antibodies market globally. According to the World Health Organization, cancer is the second leading cause of death worldwide, accounting for an estimated 9.6 million deaths, or one in six deaths, in the year 2018.

Lung cancer, prostate cancer, colorectal cancer, and liver cancer are the most common types of cancer in men, while breast cancer, colorectal cancer, lung cancer, cervical cancer and thyroid cancer are the most common among women. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market. The largest part of cancer immunotherapies involved monoclonal antibodies as monoclonal antibodies have more potential to offer less toxic and efficient therapy to the patients. They are used to treat a wide array of diseases related to autoimmune, inflammatory and especially cancer.

The growing investment in R&D in genomics in European countries such as UK is also driving the growth of the market in the forecast period. For instance, In 23 October 2021 £5 billion pound package in R&D in genomics has been sanctioned by UK government. As part of the package, Genomics England will receive funding to support new initiatives, such as ‘Generation Genome,’ a national pilot of 100,000 newborns to use genome sequencing to detect rare diseases. The new technology will enable doctors to detect over 200 conditions compared to existing tests which can just identify nine - potentially saving 3,000 babies per year.

Regulatory guidelines for monoclonal antibodies related to cancer is likely to hamper the market growth

The regulatory guidelines for monoclonal antibodies related to cancer is a highly rigorous process in most of the regions, globally. The guidelines provide a comprehensive description of the manufacturing processes including quality, good manufacturing practices, process validation, potential for degradation, and the need for stability studies. A stringent regulatory scenario exists globally, such as the US FDA, the European Medicines Agency (EMA), and the Korean FDA. Similar to biologics, biosimilar also faces similar restrictions for getting the approval of monoclonal antibodies in the market. Since it is a time-consuming process, it is considered as one of the major hindering factors for this market. Other factors that restrains the growth of the cancer monoclonal antibodies market are long duration of research and development before clinical trials and the rise in the failures of mAbs in clinical trials.

COVID-19 Impact Analysis

The COVID-19 pandemic has negatively impacted healthcare systems globally and majorly on the oncology segment. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types including acute myeloid luekaemia. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the cancer monoclonal antibodies market.

Segment Analysis

Trastuzumab (Herceptin) segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

Trastuzumab (Herceptin) is a monoclonal antibody used to treat breast cancer. It is also an approved first-line treatment for HER2+ metastatic cancer of the stomach or gastro-oesophagal junction. According to Roche’s (manufacturer of the drug) annual report 2019, the annual sales revenue generated from the drug Herceptin (oncology) was 69,82 (in million Swiss francs) in 2018 and 60,39 (in million Swiss francs). The country witnessed continued growth, mainly, due to the longer duration of treatment in combination with Perjeta.

However, the common side effects (fever, infection, cough, and rash, among others) and severe side effects (heart failure, allergic reaction, and lung disorders) are associated with the drug. The drug may also result in unnecessary issues for the baby if taken during pregnancy. These side effects may affect the adoption rate and, hence, may act as an inhibiting factor.

Geographical Analysis

North America region holds the largest market share of global cancer monoclonal antibodies market

North America dominates the global cancer monoclonal antibodies market due to the well-established healthcare infrastructures, increased spending by the government for infection control and management, and the rising prevalence of lifestyle-related diseases.

According to the Breast Cancer Organization in 2018, it was estimated that over 2,66,120 cases of invasive breast cancer were diagnosed in women in the United States, along with 63,960 new cases of non-invasive (in situ) breast cancer. With the approval of murine cancer monoclonal antibodies, followed by chimeric and fully human cancer monoclonal antibodies, the sales and the rate of product approvals have increased over the past few years.

Moreover, depending on the high percentage of molecules that are in the pipeline, this scenario may change. Human monoclonal antibody (mAb) is the fastest-growing category in the market. Additionally, with the trend toward developing targeted therapeutics, the focus on fully-humanized cancer monoclonal antibodies is expected to increase, owing to perceived low-level of immunogenicity of these agents. The first human mAb was approved by the United States FDA, in 2002. Since then, many human mAbs have received the FDA approval and few are in the phase-3 studies. Sales of Rituxan (rituximab) grew by 5% in 2015, propelled by the strong demand in the country. These factor is driving the growth of the market in the region.

Competitive Landscape

The cancer monoclonal antibodies market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genmab AS, GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG, and Merck & Co., Inc, Spectrum Pharmaceuticals Inc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the cancer monoclonal antibodies market globally.

Amgen Inc.

Overview: Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures, and markets medicines for grievous illnesses. The Company focuses on human therapeutics and concentrates on innovating novel medicines based on cellular and molecular biology.

Product Portfolio:

Vectibix (panitumumab): Vectibix® in combination with FOLFOX chemotherapy is designed for patients with wild-type RAS metastatic colorectal cancer (mCRC), and a RAS test can show what type of mCRC you have.

Why Purchase the Report?

Visualize the composition of the global cancer monoclonal antibodies market segmentation by monoclonal antibodies, by therapies, by applications and region highlighting the key commercial assets and players.

Identify commercial opportunities in global cancer monoclonal antibodies market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global cancer monoclonal antibodies market - level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global cancer monoclonal antibodies market report would provide an access to an approximately 40+ market data table, 45+ figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Cancer Monoclonal Antibodies Market – By Monoclonal Antibodies

Humanized

Murine

Chimeric

Human

Rat

Immunotoxin

Immunoadhesin

Others

Global Cancer Monoclonal Antibodies Market - By Therapies

Bevacizumab (Avastin)

Rituximab (Rituxan)

Trastuzumab (Herceptin)

Cetuximab (Erbitux)

Panitumumab (Vectibix)

Other

Global Cancer Monoclonal Antibodies Market – By Applications

Non-small-cell lung cancers

Colorectal Cancer

Breast Cancer

Prostate Cancer

Blood Cancer

Glioma cancers

Bladder Cancer

Lymphoma

Ovarian Cancer

Others

Global Cancer Monoclonal Antibodies Market - By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America